Episode Details
Back to Episodes
Iovance wins with Amtagvi and the ADC train chugs on
Published 2 years, 4 months ago
Description
This week Lori, Greg and Tyler discuss the Accelerated Approval of Amtagvi, the first one-time cell therapy for solid tumors and the first TIL therapy; the FTC and HHS probe into generic drug shortages and some recent ADC-focused raises from ProfoundBio and Firefly Bio.